Revisor Wealth Management LLC Makes New $472,000 Investment in Kenvue Inc. (NYSE:KVUE)

Revisor Wealth Management LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 19,664 shares of the company's stock, valued at approximately $472,000.

A number of other large investors have also added to or reduced their stakes in KVUE. Norges Bank purchased a new position in shares of Kenvue during the 4th quarter valued at $521,348,000. Starboard Value LP bought a new stake in shares of Kenvue in the 4th quarter worth about $467,864,000. Franklin Resources Inc. grew its holdings in Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after purchasing an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after buying an additional 8,211,748 shares during the period. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

Kenvue stock traded up $0.12 during mid-day trading on Thursday, reaching $21.02. The company's stock had a trading volume of 6,093,067 shares, compared to its average volume of 16,125,551. The firm has a market cap of $40.32 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 3.25 and a beta of 0.83. The business has a 50 day moving average price of $22.69 and a 200-day moving average price of $22.33. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The company's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.28 earnings per share. Sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were issued a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.90%. Kenvue's payout ratio is presently 149.09%.

Analyst Ratings Changes

Several brokerages have recently weighed in on KVUE. Barclays upped their price target on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. Redburn Atlantic started coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target on the stock. Evercore ISI started coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective on the stock. UBS Group increased their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Finally, Canaccord Genuity Group increased their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.